[HTML] thelancet.com

[HTML][HTML] Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an …

S Wu, J Huang, Z Zhang, J Wu, J Zhang… - The Lancet Infectious …, 2021 - thelancet.com
Background SARS-CoV-2 has caused millions of deaths, and, since Aug 11, 2020, 20
intramuscular COVID-19 vaccines have been approved for use. We aimed to evaluate the …
被引用次数：256 相关文章

Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label …

S Wu, J Huang, Z Zhang, J Wu, J Zhang, H Hu, T Zhu… - 2021 - cabidigitallibrary.org
Abstract Background: SARS-CoV-2 has caused millions of deaths, and, since Aug 11, 2020,
20 intramuscular COVID-19 vaccines have been approved for use. We aimed to evaluate …

[引用][C] Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an …

S Wu, J Huang, Z Zhang, J Wu, J Zhang, H Hu… - The Lancet Infectious …, 2021 - cir.nii.ac.jp
Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based
COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised …

Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label …

S Wu, J Huang, Z Zhang, J Wu, J Zhang… - The Lancet Infectious …, 2021 - thelancet.com
Background SARS-CoV-2 has caused millions of deaths, and, since Aug 11, 2020, 20
intramuscular COVID-19 vaccines have been approved for use. We aimed to evaluate the …

Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label …

S Wu, J Huang, Z Zhang, J Wu, J Zhang… - The Lancet Infectious …, 2021 - hero.epa.gov
BACKGROUND: SARS-CoV-2 has caused millions of deaths, and, since Aug 11, 2020, 20
intramuscular COVID-19 vaccines have been approved for use. We aimed to evaluate the …
[HTML] nih.gov

[HTML][HTML] Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an …

S Wu, J Huang, Z Zhang, J Wu, J Zhang… - The Lancet. Infectious …, 2021 - ncbi.nlm.nih.gov
Background SARS-CoV-2 has caused millions of deaths, and, since Aug 11, 2020, 20
intramuscular COVID-19 vaccines have been approved for use. We aimed to evaluate the …

Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label …

S Wu, J Huang, Z Zhang, J Wu… - The Lancet …, 2021 - pubmed.ncbi.nlm.nih.gov
Background SARS-CoV-2 has caused millions of deaths, and, since Aug 11, 2020, 20
intramuscular COVID-19 vaccines have been approved for use. We aimed to evaluate the …

Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label …

S Wu, J Huang, Z Zhang, J Wu, J Zhang, H Hu… - The Lancet Infectious …, 2021 - Elsevier
Background SARS-CoV-2 has caused millions of deaths, and, since Aug 11, 2020, 20
intramuscular COVID-19 vaccines have been approved for use. We aimed to evaluate the …

Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label …

S Wu, J Huang, Z Zhang, J Wu, J Zhang… - The Lancet. Infectious …, 2021 - europepmc.org
Background SARS-CoV-2 has caused millions of deaths, and, since Aug 11, 2020, 20
intramuscular COVID-19 vaccines have been approved for use. We aimed to evaluate the …